4.1. PD-1/PD-L1 blockade Although PD-1/PD-L1 blockade therapies have shown promising results in various types of cancers, the effect of these therapies in PCa remains ambiguous. In a large phase I trial for testing the safety and efficacy of nivolumab (an anti-PD1 antibody) among 296 pat...
Only the presence of insufficient mismatch repair has been recognized by the clinical guidelines as a transversal agnostic for anti-PD1 therapy [203]. The synergistic effect of anti-D-1/PD-L1 and anti-CTLA-4 has been reported in renal cancer and melanoma [204, 205]. It has been shown ...
RIPR-PD-1 promoted the effect of checkpoint blockade and improved the therapeutic efficacy of anti-PD1 antibodies.58 In the following paragraphs, we summarize how key molecules and multiple pathways as well as noncoding RNAs regulate the expression of PD-L1 in prostate cancer cells (Figure 1; ...
Radiotherapy in combination with androgen deprivation therapy (ADT) is a standard treatment option for men with localized and locally advanced prostate cancer. However, emerging clinical evidence suggests that radiotherapy can be incorporated into multimodality therapy regimens beyond ADT, in combinations tha...
Combining PD-1 blockade with cryoablation did not show a benefit over use of either treatment alone. Addition of ADT to anti-PD1 therapy and cryoablation doubled the time to accelerated growth in the untreated tumors (p = 0.0021) and extended survival when compared to cryoablation combined with...
Prostate adenocarcinoma (PRAD) persists as the predominant non-cutaneous malignancy diagnosed in males, which is a primary contributor to cancer-related mortality globally. It is reported that the progression of prostate adenocarcinoma is associated with
The metastasis and aggressive nature of prostate cancer (PCa) has become a major malignancy related threat that concerns men’s health. The efficacy of immune monotherapy against PCa is questionable due to its lymphocyte-suppressive nature. Endoplasmic r
Advanced prostate cancer resistant to castration therapy appears to respond well to a combination of immune checkpoint blockades and treatments that target certain immune-busting cells commonly associated with poor patient prognosis and therapy resistanc
For instance, the lack of response to an anti-PD-L1 agent in malignant tumors revealed that stromal TGF-β dampens PD-1/PD-L1 blockade.20 The present study revealed that prostate cancer (PCa) cell-derived exosomes transport IL-8 into CD8+ T cells and hamper CD8+ T cell proliferation by...
Last year, Lu et al [175], demonstrated that robust synergistic responses could be achieved in mCPRC mouse models when immune checkpoint blockade (anti-CTLA4 and anti-PD1) was combined with MDSC-targeted therapy (cabozantinib and BEZ235), while the single use of either one of them engendered ...